Searchable abstracts of presentations at key conferences in endocrinology

ea0031p297 | Pituitary | SFEBES2013

Tocopherol interacts with β-mimetic effect in reproductive and respiratory tracts in the rat

Hodi Agnes , Hajagos-Toth Judit , Klukovits Anna , Seres Adrienn , Gaspar Robert

Background: It is known that reactive oxygen species (ROS) production is necessary for the signal transduction mechanism of β-adrenergic receptors.Aim: Our aim was to investigate whether antioxidant agent (α)-tocopherol-acid-succinate may reduce the effect of β-mimetic action on β(2)-adrenergic receptor regulated tissues.Methods: Tissue samples were collected from non-pregnant (trachea) and 22-day pregnant (myom...

ea0073aep410 | General Endocrinology | ECE2021

Successful treatment of nesidioblastosis during the time of pandemic: A case report

Sándor Halmi , Berta Eszter , Lengyel Inez , Toth Judit , Kanyari Zsolt , Hutkai David , Nagy V Endre , Bodor Miklos

IntroductionIn the background of persistent hyperinsulinemic hypoglycemia the insulinomas of the pancreatic beta cells may be present, but in some rare cases we fail to identify a well-defined lesion and the insulin hypersecretion is caused by nesidioblastosis, a diffuse proliferation of the pancreatic islet cells. However, the localization of the lesion is necessary for proper treatment, in certain cases finding the insulinoma is difficult and can only ...

ea0073oc3.3 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Metyrapone treatment in endogenous Cushing’s syndrome. Long term efficacy and safety results of the extension of the phase III/IV study PROMPT

Nieman Lynnette , Boscaro Marco , Carla Scaroni , Deutschbein Timo , Mezosi Emese , Driessens Natacha , Georgescu Carmen Emanuela , Hubalewska-Dydejczyk Alicja , Berker Dilek , Jarzab Barbara , Maiter Dominique , Reincke Martin , Loli Paola , Zampetti Benedetta , Atmaca Raùl M. , Badiu Corin , Beckers Albert , Bolanowski Marek , Cavagnini Francesco , Unger Nicole , Giordano Roberta , Hanzu Felicia , Terzolo Massimo , Bostnavaron Martine , Tőke Judit , Toth Miklos

BackgroundRetrospective studies led to European approval of the steroidogenesis inhibitor Metyrapone for the treatment of endogenous Cushing’s syndrome (CS). We prospectively showed good efficacy and safety of Metyrapone after 12 weeks (Wk12) treatment in the phase III/IV PROMPT study and now report results of an extension study (EXT) sponsored by HRA Pharma Rare Diseases.DesignThis was a single arm, ope...